NDANASALSPRAY, METERED2 Generics Approved
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIGRANAL is a nasal spray formulation of dihydroergotamine mesylate, an ergot-derived 5-HT1D receptor agonist approved for acute migraine treatment. It works through vasoconstriction of intracranial blood vessels and inhibition of pro-inflammatory neuropeptide release in the trigeminal system. The drug has been marketed since 1997 and represents a non-triptan alternative for migraine rescue therapy.
$0.552MPart D
LOE ApproachingDeclining
LOE-approaching product with minimal Part D claims (112 in 2023) signals limited commercial team expansion and focus on defending existing market share against newer CGRP antagonists.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
Started Mar 2010
24 enrolled
Healthy
Career Relevance
MIGRANAL shows zero linked job openings, reflecting its LOE-approaching lifecycle and low commercial priority. Working on this product implies involvement in a legacy brand facing margin pressure and declining market relevance rather than growth or innovation.
Company
Worked on MIGRANAL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.